MX2012011881A - Metodos para tratar trastornos metabolicos de glucosa. - Google Patents

Metodos para tratar trastornos metabolicos de glucosa.

Info

Publication number
MX2012011881A
MX2012011881A MX2012011881A MX2012011881A MX2012011881A MX 2012011881 A MX2012011881 A MX 2012011881A MX 2012011881 A MX2012011881 A MX 2012011881A MX 2012011881 A MX2012011881 A MX 2012011881A MX 2012011881 A MX2012011881 A MX 2012011881A
Authority
MX
Mexico
Prior art keywords
methods
metabolic disorders
glucose metabolic
treating glucose
treating
Prior art date
Application number
MX2012011881A
Other languages
English (en)
Inventor
Kevin Ruff
Original Assignee
Kevin Ruff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kevin Ruff filed Critical Kevin Ruff
Publication of MX2012011881A publication Critical patent/MX2012011881A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/57Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

En un aspecto, la invención se refiere a métodos para tratar una enfermedad o condición asociada con metabolismo anormal de glucosa. En otro aspecto, la invención se refiere a un método para reducir incidencia o progresión de diabetes mellitus dependiente de insulina. Los métodos incluyen administrar oralmente a un mamífero en necesidad de ello una cantidad efectiva de una composición, la cual incluye un material que se presenta naturalmente derivado de cascarán de huevo, membrana de cascarón de huevo, o una combinación de los mismos.
MX2012011881A 2010-04-12 2011-04-12 Metodos para tratar trastornos metabolicos de glucosa. MX2012011881A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32330310P 2010-04-12 2010-04-12
PCT/US2011/032103 WO2011130261A1 (en) 2010-04-12 2011-04-12 Methods for treating glucose metabolic disorders

Publications (1)

Publication Number Publication Date
MX2012011881A true MX2012011881A (es) 2013-04-19

Family

ID=44798988

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012011881A MX2012011881A (es) 2010-04-12 2011-04-12 Metodos para tratar trastornos metabolicos de glucosa.

Country Status (13)

Country Link
US (2) US8679551B2 (es)
EP (2) EP2842563B1 (es)
CN (2) CN103002736B (es)
AU (1) AU2011240764B2 (es)
CA (1) CA2796336C (es)
CY (2) CY1116808T1 (es)
ES (2) ES2528413T3 (es)
MX (1) MX2012011881A (es)
NZ (1) NZ602949A (es)
PL (2) PL2842563T3 (es)
PT (2) PT2842563T (es)
RS (2) RS55025B1 (es)
WO (1) WO2011130261A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2440390B1 (es) * 2012-07-25 2014-11-13 Bioibérica, S.A. Composiciones para el tratamiento del sobrepeso y de la obesidad
JP5998350B2 (ja) * 2013-03-27 2016-09-28 国立大学法人 東京大学 卵殻膜成分を含む肝保護剤ならびにそれを用いた医薬組成物、食品添加物および食品
JP2014231487A (ja) * 2013-05-28 2014-12-11 国立大学法人 東京大学 卵殻膜成分を含むサーチュイン遺伝子活性化剤ならびにそれを用いた組成物
US20140363519A1 (en) * 2013-06-11 2014-12-11 The University Of Tokyo Activator of gene expression of molecular chaperone gene comprising eggshell membrane component and composition thereof
JP2016523966A (ja) * 2013-07-08 2016-08-12 インターナショナル ディハイドレーティッド フーズ, インコーポレイテッド 家禽から調製した組成物およびその使用方法
US11478504B2 (en) 2013-07-08 2022-10-25 International Dehydrated Foods, Inc. Compositions and methods for preventing/treating metabolic syndrome
JP6056064B2 (ja) * 2013-11-29 2017-01-11 国立大学法人 東京大学 卵殻膜成分を含むインスリン抵抗性改善剤ならびにそれを用いた組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652221A (en) * 1994-11-07 1997-07-29 The University Of Virginia Patent Foundation Method of treating defective glucose metabolism using synthetic insulin substances
GB0213612D0 (en) * 2002-06-13 2002-07-24 Novartis Nutrition Ag Organic compounds
DE20213669U1 (de) * 2002-09-02 2004-02-12 Ewald Speth Antriebstechnik Gmbh Direkt angetriebene Antriebsachse mit einer an axial festgelegtes Sonnenritzel aufweisenden Getriebestufe
US20080063677A1 (en) * 2004-03-10 2008-03-13 New Life Resources, Llc Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations
KR100662903B1 (ko) * 2004-12-14 2007-01-02 건국대학교 산학협력단 글루코사민 하이드로클로라이드를 함유하는 당뇨 질환치료용 의약 조성물
CA2556343A1 (en) * 2005-09-01 2007-03-01 Purepharm Inc. Synthetic nutritional formulations
CN102325535A (zh) * 2009-02-23 2012-01-18 帝斯曼知识产权资产管理有限公司 用于炎性病症的cajanus提取物和葡糖胺

Also Published As

Publication number Publication date
CN103002736A (zh) 2013-03-27
PL2557920T3 (pl) 2015-04-30
ES2579340T3 (es) 2016-08-10
CA2796336A1 (en) 2011-10-20
WO2011130261A1 (en) 2011-10-20
PL2842563T3 (pl) 2016-12-30
EP2842563B1 (en) 2016-05-25
RS53826B1 (en) 2015-06-30
AU2011240764A1 (en) 2012-11-08
PT2842563T (pt) 2016-07-14
CN105250335A (zh) 2016-01-20
US8927032B2 (en) 2015-01-06
CN105250335B (zh) 2019-10-29
NZ602949A (en) 2014-11-28
AU2011240764B2 (en) 2014-07-10
CY1116808T1 (el) 2017-03-15
US20130089619A1 (en) 2013-04-11
EP2557920A1 (en) 2013-02-20
CA2796336C (en) 2018-06-05
ES2528413T3 (es) 2015-02-10
EP2557920B1 (en) 2014-11-12
PT2557920E (pt) 2015-02-05
EP2842563A1 (en) 2015-03-04
US20140193516A1 (en) 2014-07-10
RS55025B1 (sr) 2016-11-30
CY1117799T1 (el) 2017-05-17
US8679551B2 (en) 2014-03-25
CN103002736B (zh) 2015-11-25
EP2557920A4 (en) 2013-10-23

Similar Documents

Publication Publication Date Title
MX2012011881A (es) Metodos para tratar trastornos metabolicos de glucosa.
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
PH12016501607A1 (en) Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
MY176863A (en) Ibat inhibitors for treatment of metabolic disorders and related conditions
WO2010123930A3 (en) Chemosensory receptor ligand-based therapies
WO2013158928A3 (en) Chemosensory receptor ligand-based therapies
MX344925B (es) Composiciones de insulina y cromo para el tratamiento y prevención de diabetes, hipoglucemia y alteraciones relacionadas.
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
MX360317B (es) Derivados de exendina-4 funcionalizada.
EP2506717A4 (en) METHOD OF USING DOPAMINE RECAPTURE INHIBITORS AND THEIR ANALOGUES TO TREAT DIABETES SYMPTOMS AND DELAYING OR PREVENTING DIABETES ASSOCIATED DISEASE CONDITIONS
WO2013055834A3 (en) Er stress relievers in beta cell protection
EP2560660A4 (en) THERAPIES BASED ON CHEMOSOUS RECEPTOR LIGANDS
GB201101459D0 (en) Novel compounds and thier effects on fedding behaviour
WO2012097213A3 (en) Methods for diagnosing and treating eye-length related disorders
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
GB201317446D0 (en) Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
MX362527B (es) Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
WO2013041519A9 (en) Ror gamma modulators
AP2011005978A0 (en) 2, 4 diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation.
WO2014036528A3 (en) Agents useful for treating obesity, diabetes and related disorders
MX2011012666A (es) Usos de anticuerpos il-1beta y sus fragmentos de union relacionados con eventos cardiovasculares.
WO2011063161A3 (en) Epithelial membrane protein-2 (emp2) and proliferative vitreoretinopathy (pvr)
WO2010106542A3 (en) USE OF NKp46 FOR PREVENTING DIABETES
WO2009098355A8 (en) Novel use of probiotics
EP2533796A4 (en) METHOD FOR THE TREATMENT OF GLUCOSE TISSUE CHANGES